Compare MSI & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSI | ZTS |
|---|---|---|
| Founded | 1928 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6B | 53.9B |
| IPO Year | N/A | 2013 |
| Metric | MSI | ZTS |
|---|---|---|
| Price | $380.23 | $126.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $491.00 | $174.60 |
| AVG Volume (30 Days) | 1.6M | ★ 6.2M |
| Earning Date | 02-12-2026 | 02-12-2026 |
| Dividend Yield | 1.28% | ★ 1.68% |
| EPS Growth | ★ 36.31 | 11.64 |
| EPS | ★ 12.46 | 5.94 |
| Revenue | ★ $11,313,000,000.00 | $9,397,000,000.00 |
| Revenue This Year | $8.75 | $3.04 |
| Revenue Next Year | $8.25 | $4.98 |
| P/E Ratio | $30.28 | ★ $21.22 |
| Revenue Growth | ★ 6.18 | 2.68 |
| 52 Week Low | $359.36 | $115.25 |
| 52 Week High | $492.22 | $177.40 |
| Indicator | MSI | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 54.08 | 58.09 |
| Support Level | $375.00 | $121.12 |
| Resistance Level | $380.10 | $125.53 |
| Average True Range (ATR) | 6.28 | 2.56 |
| MACD | 2.77 | 1.11 |
| Stochastic Oscillator | 99.91 | 92.83 |
Motorola Solutions is a leading provider of communications and analytics, primarily serving public safety departments as well as schools, hospitals, and businesses. The bulk of the firm's revenue comes from sales of land mobile radios and radio network infrastructure, but the firm also sells surveillance equipment, dispatch software, and other networking capabilities. Most of Motorola's revenue comes from government agencies, while roughly 25% comes from schools and private businesses. Motorola has customers in over 100 countries and in every state in the United States.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.